Amneal to Participate in Upcoming Investor Conferences

About this update from Amneal Pharmaceuticals, Inc.

[{"type":"image","alt":"Amneal Pharmaceuticals LLC","displaySize":"","headline":null,"caption":"Amneal Pharmaceuticals LLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":133,"url":"https://media.zenfs.com/en/globenewswire.com/3fb94de605ddf51d0434711194cc8cc5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MVfw43aIERtNjvnCPqXoHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3fb94de605ddf51d0434711194cc8cc5","width":300,"height":133}},"lazy":false},{"type":"text","content":"BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in following upcoming investor conferences:","length":272,"tagName":"p"},{"type":"text","content":"Piper Sandler 2025 Healthcare ConferenceDate: December 3, 2025Fireside Chat: Wednesday, December 3, 2025, at 9:30AM ESTLocation: New York, NY","length":144,"tagName":"p"},{"type":"text","content":"J.P. Morgan 2026 Healthcare ConferenceDate: January 12-15, 2026Presentation: Tuesday, January 13, 2026, at 4:30PM PSTLocation: San Francisco, CA","length":147,"tagName":"p"},{"type":"text","content":"A webcast of the presentations will be available on Amneal’s Investor Relations website at www.amneal.com/investors. Replays will be available for a limited time following each event.","length":183,"tagName":"p"},{"type":"text","content":"About Amneal","length":12,"tagName":"p"},{"type":"text","content":"Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 290 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more informa...

More updates from Amneal Pharmaceuticals, Inc.